Patients can stop semaglutide without adverse effects
Administered as a once-weekly subcutaneous injection, it works by mimicking the action of the naturally occurring hormone GLP-1, which helps regulate blood glucose levels by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying
Hormonal changes during pregnancy can trigger melasma, often referred to as the "mask of pregnancy." It may fade postpartum but can persist in some cases
Reconstituted peptides should be stored in the refrigerator and used within 3-4 weeks for optimal potency
Avoid frequent temperature cycling by minimizing door-open time
This triple agonist design, developed by Eli Lilly under the research code LY3437943, represents a fundamentally different approach from semaglutide (which targets only GLP-1) or tirzepatide (which targets GLP-1 and GIP)